<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04556435</url>
  </required_header>
  <id_info>
    <org_study_id>2019-5606</org_study_id>
    <nct_id>NCT04556435</nct_id>
  </id_info>
  <brief_title>Breath Analysis in Early Stage Lung Cancer Using Infrared Spectroscopy</brief_title>
  <official_title>Analysis of Volatile Chemicals in the Breath of Lung Cancer Patients Using Infrared Spectroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Picomole Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Picomole Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to sample and analyze volatile organic compounds (VOCs) from lung&#xD;
      cancer patients and individuals without lung cancer (&quot;healthy&quot; controls). The breath sample&#xD;
      analysis will help investigators describe and identify profiles of VOCs found in the breath&#xD;
      of patients with lung cancer when compared to normal breath profiles using infrared&#xD;
      spectroscopy. This work will help validate early proof of concept results conducted with&#xD;
      prototype technology and later stage NSCLC breath samples, and inform future breath testing&#xD;
      analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Globally, lung cancer accounts for the most cancer deaths in both sexes combined. It is&#xD;
      believed to develop slowly through progressive accumulation of genetic mutations, hence the&#xD;
      disease allows time for diagnosis and curative surgical treatment. Five year survival rates&#xD;
      for non-small-cell lung carcinoma (NSCLC) can range from 57-61% when detected in the early&#xD;
      stages of disease. This is compared with a survival rate of approximately 6% once distant&#xD;
      metastases are present. However, disease diagnosis typically occurs when it has progressed to&#xD;
      an advanced stage when patients present with signs and symptoms. Therefore, technologies&#xD;
      capable of asymptomatic disease detection will significantly impact lung cancer specific&#xD;
      mortality. Metabolomic profiling of cancer measures compounds produced as a result of&#xD;
      cellular activity including volatile organic compounds (VOCs) in exhaled breath. Infrared&#xD;
      spectroscopy is a proven technique for breath analysis that can measure chemical&#xD;
      concentrations in the parts per trillion range for certain VOCs. When coupled with machine&#xD;
      learning techniques, this has the potential to be a novel approach for disease detection&#xD;
      using exhaled breath.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">April 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>VOC spectral profile differences</measure>
    <time_frame>30 days after completion</time_frame>
    <description>VOC spectral profiles will be compared between cohorts to identify statistical differences.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>LC Group</arm_group_label>
    <description>Participants will provide two breath samples by exhaling into the breath sampling apparatus and complete the Medical Questionnaire (medications, lifestyle, demographics, smoking history) and survey (lung health). Information related to LC diagnosis (histologic sub-type, tumor stage) will be collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Participants will provide two breath samples by exhaling into the breath sampling apparatus and complete the Medical Questionnaire (medications, lifestyle, demographics, smoking history) and survey (lung health).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This study will analyze breath samples from study participants with diagnosed lung&#xD;
        adenocarcinoma not currently receiving curative treatment and matched control participants&#xD;
        without lung cancer. Prospective participants will be pre-screened prior to being&#xD;
        approached about the study. Those scheduled for upcoming appointments will undergo a chart&#xD;
        review to determine whether they meet eligibility criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        LC Group:&#xD;
&#xD;
          -  ≥ 18 years;&#xD;
&#xD;
          -  Able to give informed consent;&#xD;
&#xD;
          -  Eligible for lung cancer screening or lung cancer follow-up testing (biopsy, surgery);&#xD;
&#xD;
          -  Clinical evidence of lung cancer (metastatic or primary), inclusive of those receiving&#xD;
             non-curative treatment, has not yet been treated or is not currently on treatment;&#xD;
&#xD;
          -  No history of or any other active cancer;&#xD;
&#xD;
          -  Able to provide a breath sample;&#xD;
&#xD;
        Control Group:&#xD;
&#xD;
          -  ≥ 18 years;&#xD;
&#xD;
          -  Able to give informed consent;&#xD;
&#xD;
          -  Eligible for lung cancer screening or lung cancer follow-up testing (biopsy, surgery);&#xD;
&#xD;
          -  No history of lung cancer or any other active cancer and is eligible for lung cancer&#xD;
             screening;&#xD;
&#xD;
          -  Able to provide a breath sample;&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Has received or is currently receiving curative treatment and may no longer have lung&#xD;
             cancer;&#xD;
&#xD;
          -  Cannot give informed consent;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Mahtabifard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mia Martinez</last_name>
    <phone>714-456-3757</phone>
    <email>miam@hs.uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cesar Figueroa, MD</last_name>
    <email>figuerc1@hs.uci.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mia Martinez</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mia Martinez</last_name>
      <phone>714-456-3757</phone>
      <email>miam@hs.uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cesar Figueroa, MD</last_name>
      <email>figuerc1@hs.uci.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf</url>
    <description>American Cancer Society. Cancer Facts &amp; Figures 2019.</description>
  </link>
  <link>
    <url>https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html</url>
    <description>American Cancer Society. Non-Small Cell Lung Cancer Survival Rates (2016)</description>
  </link>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Henderson B, Khodabakhsh A, Metsälä M, Ventrillard I, Schmidt FM, Romanini D, Ritchie GAD, Te Lintel Hekkert S, Briot R, Risby T, Marczin N, Harren FJM, Cristescu SM. Laser spectroscopy for breath analysis: towards clinical implementation. Appl Phys B. 2018;124(8):161. doi: 10.1007/s00340-018-7030-x. Epub 2018 Jul 28.</citation>
    <PMID>30956412</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Volatile Organic Compounds</keyword>
  <keyword>Breath Analysis</keyword>
  <keyword>Infrared Spectroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make IPD available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

